People20d
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand Version
On Thursday, Dec. 19, the U.S. Food and Drug Administration announced in a statement that after two years of being in shortage, tirzepatide — the active ingredient in Zepbound and its counterpar ...
NBC New York23d
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
The Food and Drug Administration announced that branded tirzepatide, the active ingredient in Eli Lilly's weight loss drug Zepbound, is no longer in short supply. That decision will largely ...
UPI27d
FDA says shortage of GLP-1 drug tirzepatide is over
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over. Tirzepatide includes blockbuster ...
MedPage Today28d
FDA Says Compounded Tirzepatide Must Exit the Market
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The shortage of the diabetes and obesity injectable tirzepatide (Mounjaro, Zepbound) has been resolved, the FDA ...
AOL20d
What is Compounded Tirzepatide? Here's What You Need to Know
If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food and Drug Administration) under the brand names Mounjaro and Zepbound.
Yahoo22d
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
Tirzepatide, the active ingredient in Zepbound and Mounjaro, is no longer in short supply, the FDA says. Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025 ...
Yahoo27d
The FDA says the Zepbound shortage is over. That's rattling the weight loss industry
The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli Lilly’s popular diabetes and weight-loss drugs Mounjaro and Zepbound ...
Benzinga.com27d
Hims & Hers Health Are Falling Today: What's Going On?
The FDA announced that the tirzepatide injection shortage is resolved. Hims & Hers Health, Inc.'s stock fell 6.90%, reflecting market concerns over regulatory updates and supply chain stability.
Kansas City Star10d
Ask a Health Professional: How do semaglutide and tirzepatide support wellness goals?
Medications like semaglutide and tirzepatide have gained significant attention for their impressive weight-loss effects, but they do much more than just helping you shed pounds. Let’s dive into ...